EDITAS MEDICINE, INC.
Ownership & governance
Executives 5Directors 6Avg age 62Avg tenure 4y
GO
Gilmore O’Neill
Chief Executive Officer
Age 61Since 2022-05-31Profile →
+10
Executives5
GO
Gilmore O’Neill→
Chief Executive Officer
Age 61Since 2022-05-31
AP
Amy Parison→
Director of Finance/CFO
Age 40Since 2025-03-27
GW
Gregory Whitehead
Chief Tech/Sci/R&D Officer
—Since 2022-09-30
LB
Linda Burkly
Chief Tech/Sci/R&D Officer
Age 69Since 2023-07-23
TL
Tom Love
Human Resources Officer
—Since 2024-03-31
Board of directors6
AH
Andrew Hirsch→
Director/Board Member
Age 55Since 2017-05-29
JH
Jessica Hopfield→
Chairman
Age 61Since 2024-12-30
DS
David Scadden→
Director/Board Member
Age 73Since 2019-02-05
BC
Bernadette Connaughton→
Director/Board Member
Age 67Since 2021-10-25
GO
Gilmore O’Neill→
Director/Board Member
Age 61Since 2022-05-31
EL
Elliott Levy→
Director/Board Member
Age 67Since 2023-04-10
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| TCG Crossover Management LLC | 7.24 % | 11,111,111 |
| RA Capital Management LP | 5.792 % | 8,889,000 |
| Commodore Capital LP | 5.792 % | 8,889,000 |
| BlackRock Advisors LLC | 5.675 % | 8,709,469 |
| Vanguard Capital Management LLC | 2.74 % | 4,204,369 |
Catalog · 2026-07-09
Proxy officers16
| Name | Role | Since | Shares |
|---|---|---|---|
| Jessica Hopfield | Chairman | 2024-12-30 | - |
| Amy Parison | Director or executive officer | — | 122,427 |
| Amy Parison | Director or executive officer | — | 122,427 |
| Andrew Hirsch | Director/Board Member | 2017-05-29 | - |
| Andrew Hirsch | Director or executive officer | 2017-01-01 | 183,728 |
| Andrew Hirsch | Director or executive officer | 2017-01-01 | 183,728 |
| Bernadette Connaughton | Director/Board Member | 2021-10-25 | - |
| David Scadden | Director/Board Member | 2019-02-05 | - |
Proxy · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 6.1Range 1–15Analysts 10
1Mean 6.115
- Buy 9
- Hold 2
- Strong sell 2
Broker actions40 of 133
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Wells Fargo | Upgrade | Overweight | 6 | 2026-10-08 |
| Guggenheim | Upgrade | Buy | 5 | 2026-09-23 |
| Ladenburg Thalmann | Initiated | Buy | 6 | 2026-08-18 |
| Chardan Capital | Maintained | Buy | 4 | 2026-05-05 |
| Jones Trading | Upgrade | Buy | 8 | 2026-03-10 |
| Chardan Capital | Maintained | Buy | 3.5 | 2026-03-09 |
| HC Wainwright & Co. | Reiterated | Buy | 5 | 2025-09-05 |
| Wells Fargo | Maintained | Equal-Weight | 4 | 2025-09-03 |
| HC Wainwright & Co. | Maintained | Buy | 5 | 2025-08-15 |
| Baird | Maintained | Outperform | 6 | 2025-08-13 |
| Baird | Maintained | Outperform | 4 | 2025-05-13 |
| HC Wainwright & Co. | Initiated | Buy | 3 | 2025-04-28 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.